CureVac N.V. (CVAC)
NASDAQ: CVAC · Real-Time Price · USD
4.410
-0.050 (-1.12%)
At close: Jun 6, 2025, 4:00 PM
4.310
-0.100 (-2.27%)
After-hours: Jun 6, 2025, 7:35 PM EDT
CureVac Employees
As of December 31, 2024, CureVac had 983 total employees, including 825 full-time and 158 part-time employees. The number of employees decreased by 189 or -16.13% compared to the previous year.
Employees
983
Change (1Y)
-189
Growth (1Y)
-16.13%
Revenue / Employee
$575,829
Profits / Employee
$198,637
Market Cap
992.95M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
CVAC News
- 18 days ago - CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates - Accesswire
- 22 days ago - CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE - Accesswire
- 2 months ago - CureVac N.V. (CVAC) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update - Accesswire
- 2 months ago - CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025 - Accesswire
- 2 months ago - CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer - Accesswire
- 2 months ago - CureVac Shares Rise on Patent Confirmation Amid BioNTech Lawsuit - Market Watch
- 2 months ago - European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps - Benzinga